CMO Merdad Parsey (Gilead)

Gilead hits the brakes on a tri­fec­ta of mid- and late-stage stud­ies for their trou­bled fil­go­tinib pro­gram. It's up to the FDA now

Gilead $GILD ex­ecs haven’t de­cid­ed ex­act­ly what to do with fil­go­tinib in the wake of the slap­down at the FDA on their rheuma­toid arthri­tis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.